for the Period Ended 30 June 2021
Directors report | |
Profit and loss | |
Balance sheet | |
Additional notes | |
Balance sheet notes |
Directors' report period ended
The directors present their report with the financial statements of the company for the period ended 30 June 2021
Principal activities of the company
Political and charitable donations
Additional information
HOLDING COMPANYSatipharm Europe Limited is a wholly owned subsidiary of Satipharm AG, a company incorporated in Switzerland. Satipharm AG is in turn wholly owned by Cann Group Limited, a company incorporated in Australia. Cann Group Limited acquired the entire share capital of Satipharm AG during the period.
Directors
The director shown below has held office during the whole of the period from
1 September 2020 to 30 June 2021
The director shown below has held office during the period of
1 September 2020 to 9 October 2020
The director shown below has held office during the period of
1 September 2020 to 8 September 2020
The directors shown below have held office during the period of
10 March 2021 to 30 June 2021
Secretary
The above report has been prepared in accordance with the special provisions in part 15 of the Companies Act 2006
This report was approved by the board of directors on
And signed on behalf of the board by:
Name:
Status: Director
for the Period Ended
10 months to 30 June 2021 | 2020 | |
---|---|---|
| £ | £ |
Turnover: | | |
Cost of sales: | ( | ( |
Gross profit(or loss): | ( | ( |
Administrative expenses: | ( | ( |
Operating profit(or loss): | ( | ( |
Profit(or loss) before tax: | ( | ( |
Profit(or loss) for the financial year: | ( | ( |
As at
Notes | 10 months to 30 June 2021 | 2020 | |
---|---|---|---|
| £ | £ | |
Current assets | |||
Stocks: | 3 | | |
Debtors: | 4 | | |
Total current assets: | | | |
Creditors: amounts falling due within one year: | 5 | ( | ( |
Net current assets (liabilities): | ( | ( | |
Total assets less current liabilities: | ( | ( | |
Total net assets (liabilities): | ( | ( | |
Capital and reserves | |||
Called up share capital: | | | |
Profit and loss account: | ( | ( | |
Total Shareholders' funds: | ( | ( |
The notes form part of these financial statements
This report was approved by the board of directors on
and signed on behalf of the board by:
Name:
Status: Director
The notes form part of these financial statements
for the Period Ended 30 June 2021
Basis of measurement and preparation
Turnover policy
Other accounting policies
for the Period Ended 30 June 2021
10 months to 30 June 2021 | 2020 | |
---|---|---|
Average number of employees during the period | | |
for the Period Ended 30 June 2021
10 months to 30 June 2021 | 2020 | |
---|---|---|
£ | £ | |
Stocks | | |
Total | | |
for the Period Ended 30 June 2021
10 months to 30 June 2021 | 2020 | |
---|---|---|
£ | £ | |
Trade debtors | | |
Prepayments and accrued income | | |
Other debtors | | |
Total | | |
for the Period Ended 30 June 2021
10 months to 30 June 2021 | 2020 | |
---|---|---|
£ | £ | |
Trade creditors | | |
Accruals and deferred income | | |
Other creditors | | |
Total | | |